Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement | Zendy

Vasileios Chortis | Zendy; Angela E. Taylor | Zendy; Petra Schneider | Zendy; Jeremy Tomlinson | Zendy; Beverly Hughes | Zendy; Donna O’Neil | Zendy; Rossella Libé | Zendy; Bruno Allolio | Zendy; Xavier Bertagna | Zendy; Jérôme Bertherat | Zendy; Felix Beuschlein | Zendy; Martin Faßnacht | Zendy; Niki Karavitaki | Zendy; Massimo Mannelli | Zendy; Franco Mantero | Zendy; Giuseppe Opocher | Zendy; Emilio Porfiri | Zendy; Marcus Quinkler | Zendy; Mark Sherlock | Zendy; Massimo Terzolo | Zendy; Peter Nightingale | Zendy; Cedric Shackleton | Zendy; Paul M. Stewart | Zendy; Stefanie Hahner | Zendy; Wiebke Arlt | Zendy

Open Access

Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement

Author(s) -

Vasileios Chortis,

Angela E. Taylor,

Petra Schneider,

Jeremy Tomlinson,

Beverly Hughes,

Donna O’Neil,

Rossella Libé,

Bruno Allolio,

Xavier Bertagna,

Jérôme Bertherat,

Felix Beuschlein,

Martin Faßnacht,

Niki Karavitaki,

Massimo Mannelli,

Franco Mantero,

Giuseppe Opocher,

Emilio Porfiri,

Marcus Quinkler,

Mark Sherlock,

Massimo Terzolo,

Peter Nightingale,

Cedric Shackleton,

Paul M. Stewart,

Stefanie Hahner,

Wiebke Arlt

Publication year - 2012

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-2851

Subject(s) - mitotane , adrenocortical carcinoma , medicine , endocrinology , glucocorticoid , cyp3a4 , context (archaeology) , interquartile range , chemistry , cytochrome p450 , biology , metabolism , paleontology

Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor. Mitotane is considered an adrenolytic substance, but there is limited information on distinct effects on steroidogenesis. However, adrenal insufficiency and male hypogonadism are widely recognized side effects of mitotane treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research